16th Annual Conference of the Indian Society for Clinical Research
Demystifying Innovations in Clinical Research
(Innovation. Responsibility. Humanism)
23-25 February 2023, Pullman, New Delhi

General Information and eligibility

ISCR’s 16th Annual Conference Scientific Committee solicits original clinical research:
  • Conducted and completed between 2019 to 2022.
  • Abstracts submitted can be from Observational or Interventional (study design) studies.
  • Clinical research conducted should address important questions in patient management, research ethics, Investigator/Hospital site operational issues with consideration given to clinical research relevant to needs of India.
  • Clinical Researchers, faculty and students from Medicine, Pharmacy, Nursing and Biological sciences (post-graduate, undergraduate and super-speciality) are eligible.
  • Abstract submitted must not have been presented at any of the previous Annual ISCR Conferences (either as Oral or Poster presentation)
  • Abstract(s) can be submitted via online application process with the details mentioned in the application form.
  • The abstract submitted should not exceed 400 words (maximum 1 page long).
  • The author submitting abstract can indicate his/her preference for presenting the study in oral or poster session by selecting the appropriate category while filing up the application form.
  • The abstract should be structured and contain title, authors, address of institution(s), aims, objectives, brief methodology, results and conclusion (See Annexure 1 below for details).
  • The final decision to accept the abstract for ORAL and/or POSTER session will be made by Scientific review committee, this decision will be final and binding.
  • The last date for submission of abstract is 15th November 2022.
  • The author(s) who submitted the Abstract and which have been shortlisted for Oral or Poster session will be informed on 10 th January 2023 or earlier
  • For all accepted Abstracts, presenters will be informed and need to register for the Conference (Paid registration), to make Oral/ -Poster presentation on allotted day and time.
Annexure 1
Font type for Abstract Times New Roman
Title of Abstract Font size - 12 and in bold
Author Name(s) Font size – 12 Surname/Last Name (in full), first Name, staring from first to last author (underline presenting author’s name)
Institution Name Font Size - 12 Institute name, city, state, country
Font size - 10
Headings like Background, methods...
in CAPITAL letters and in bold
  • Title: Effect of a collaborative care model on depressive symptoms and cardiometabolic trajectories in patients with co-morbid depression and diabetes in India (INDEPENDENT Study)
  • Authors: B. Bhavani Sundari , Patel Shivani , S. Poongothai , R.M. Anjana , R. Pradeepa , R. Kamalesh , Rao Deepa , Chwastiak Lydia , N. Tandon , G.R. Sridhar , S.R. Aravind , S. Radha , S. Rajesh , M.K. Ali , V. Mohan
  • Institution: Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai. University of Washington, Seattle, United States. All India Institute of Medical Sciences, New Delhi, India.Endocrine and Diabetes Centre, Visakhapatnam, India. DIACON Hospital, Diabetes Care and Research Centre, Bangalore India. Fortis Malar Hospital, Chennai, India. Rollins School of Public Health, Emory University, Atlanta, United States.
  • Background: Comorbid depression and type 2 diabetes are associated with poor glycaemic control, increased complications, poor self – management along with increased health care use, compared to either condition alone.
  • Objective: We examined the effect of an integrated care model that brings depression care into diabetes clinics (INtegrating DEPrEssioN and Diabetes treatmENT [INDEPENDENT]) on trajectories of depressive symptoms of the participants at 12, 24 and 36 months.
  • Methods: Participants with comorbid depression and diabetes were recruited from four sites for this study. The participants at 24 months and 36 months, who had at least a 50% reduction in Patient Health Questionnaire 9(PHQ-9) scores or a reduction of at least 0.5 percentage points in HbA1c or 5mmHg in SBP, or 10 mg/dL in LDL cholesterol was studied. We identified groups of treatment responses over 36 months of follow-up after randomization. The participants were categorised as sustainers, when they responded to treatment at 12, 24 and 36 months, as reverters, when they responded to treatment at 12 months but did not sustain the positive response at 24 or at 36 months and non – responders, when they did not respond at the end of 12 months . The mean and 95% CI were calculated to categorise participant outcomes.
  • Results: Among 404 patients randomized, 394 completed 12 months, 378 completed 24 months and 331 completed 3 months follow-up. At 24 and 36 months, Sustainers were higher in the intervention arm compared to the control arm for ≥50% improvement in depressive symptoms (PHQ-9 scores) ( At 24 months - intervention arm (60.0 % [95%CI, 50.25%-64.18%]) Vs control arm (43 %; [95%CI, 35.82%-49.75%]) and at 36 months in the intervention arm (51.9 % [95%CI, 44.10%-59.80%]) Vs 36.2 %; [95%CI, 28.8%-43.6%]) in the control arm). Reverters of depressive symptoms at 24 months was higher in the intervention arm compared to the control arm (16.2 % [95%CI, 11.60%-22.20%]vs 5.6 %; [95%CI, 3.21%-9.91%]). Similarly in 36 months(21.2 % [95%CI, 14.70%-27.6%]vs 11.7 %; [95%CI, 6.70%-16.5%]). At 12 months, non-responders were greater in the control arm. ≥50% improvement in depressive symptoms (PHQ-9 scores) was not accomplished by intervention arm (23.7 % [95%CI, 23.33%-38.33%]) and control arm( 51.2%; [95%CI, 44.28%-58.35%]).
  • Conclusion: When intervention is provided to those with comorbid depression and diabetes, the participants who received intervention showed sustained improvement in depressive symptoms, at the end of 36 months.

Choose Category


Indian Society for Clinical Research

The Capital, 1802, 18th Floor,
Plot No. C-70,'G'Block,
Bandra Kurla Complex,
Bandra(E), Mumbai - 400 051